Hussein Yassine, MD, Keck School of Medicine at the University of Southern California, Los Angeles, CA, discusses the Phase II PreventE4 trial (NCT03613844), which examined whether omega-3 supplementation could improve cognition and delay Alzheimer’s disease (AD) onset, particularly in individuals with the APOE4 allele. The trial found that higher doses of omega-3s successfully penetrated into the brain but had no impact on cognition or hippocampal volume. Dr Yassine elaborates on additional findings and emphasizes the need for further clinical trials to clarify the relationship between omega-3s and cognitive health. This interview took place on the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
